GIP and obesity due to melanocortin 4 receptor deficiency: GLP-1 receptor agonists have been successfully used clinically for T2DM treatment, whereas GIP levels are increased in individuals with obesity and T2DM (Tasyurek et al., 2014; Holst and Rosenkilde, 2020).